Here, we report a prospective clinical study in high-risk hematology patients on posaconazole prophylaxis assessing the feasibility, safety and efficiency of discontinuing twice weekly sGM surveillance from our antifungal management strategy. The assay continued to be used only for diagnostic purposes in all patients with persistent fever over 72 h unresponsive to broad-spectrum antibiotics and those with a clinical suspicion of IFD. Other than the discontinuation of sGM surveillance, our antifungal practice and study characteristics remained as previously described with the pre-emptive surveillance strategy. 9 The endpoints to assess the effectiveness, safety and efficiency of this change in management are the incidence of probable and proven IA and IFD as revised by the European Organization for Research and treatment of Cancer and the Mycoses Study Group (EORTC/MSG), 11 the occurrence and reasons for prophylaxis discontinuation and replacement with antifungal treatment, all-cause mortality, cause of death during the risk episodes and the impact on the use of diagnostics tests. The study includes data on three different cohorts of high-risk episodes under posaconazole primary antifungal prophylaxis: patients with AML and prolonged neutropenia after chemotherapy (AML chemotherapy episodes) who started posaconazole prophylaxis 24 h after the last day of chemotherapy until neutrophil recovery 40.5 × 10 9 /L, allogeneic HCT recipients (allogeneic HCT episodes), receiving prophylaxis from day 1 after hematopoietic cell infusion and up to day 100, and transplant recipients with GvHD (GvHD episodes), who received posaconazole from the start of ⩾ 1 mg/kg of daily corticosteroids until tapering to o 10 mg of daily prednisone or equivalent. Along with sGM testing, our IFD diagnostic algorithm included computed tomographic (CT) scans, bronchoscopy and bronchoalveolar lavage with GM and additional samples for bacterial, fungal and viral microbiology in case of any pulmonary infiltrates, as well as additional cultures from blood, sputum or other relevant samples when clinically indicated. Further details on isolation measures, antifungal treatment recommendations, and other anti-microbial prophylaxis and management have been previously described. 8, 9 Posaconazole oral solution was administered following the drug's prescribing information (https://www.merckconnect.com/noxafil/prescribing-information. html). sGM tests (Platelia Aspergillus enzyme immunoassay, Bio-Rad Laboratories, Madrid, Spain) were considered positive for an optical index ⩾ 0.7 in one sample or ⩾ 0.5 in two consecutive samples. Episodes with positive sGM tests results were defined as false positive on clinical grounds if patients did not develop any other criteria of probable or proven IFD, survived the episode and remained on posaconazole prophylaxis throughout without receiving other antifungal therapy. 9 While the definition of IFD for end-point analysis follows EORTC/MSG criteria, 11 the clinical decisions to replace posaconazole prophylaxis with antifungal therapy relied in all cases on an individualized clinical judgment, including patient general condition, signs and symptoms, test results and treatment compliance, rather than on the fulfillment of EORTC/MSG criteria. 9 Our ethics committee approved the study (CEIC Bellvitge), patients signed informed consents for treatment and data collection, and study data were recorded in a specific database. Software package SPSS (version 17; http://www.spss.com) was used for statistical analysis. Descriptive and comparative analyses were done, with Fisher's exact test or chi-square analysis for differences in proportions, and variance analysis or non-parametric tests for differences between GM results. P-values are two-sided and considered statistically significant if o 0.05.
One hundred consecutive unselected high-risk hematology episodes managed with oral solution posaconazole primary prophylaxis and a diagnostic-driven protocol without sGM surveillance were included from June 2013 to August 2014 (Table 1A) . Fifty-two patients underwent 62 high-risk episodes of AML chemotherapy, 26 of allogeneic HCT and 12 of GvHD (Table 1B) . Patient demographics and high-risk episode characteristics are analogous to those in our previous pre-emptive surveillance strategy population in which additional twice weekly sGM tests were performed during the whole risk episode, except for patients' age, significantly higher for the diagnostic-driven sGM use population (57 vs 49 years; P = 0.001).
Posaconazole was well tolerated, and in the vast majority of episodes (85%) patients successfully completed their prophylaxis as initially planned (versus 83.2% with the previous pre-emptive strategy; P = NS). With the implementation of the diagnosticdriven sGM use strategy, only 39 out of 100 episodes required sGM testing (versus 262/262; 100%, P o 0.001), and only 78 sGM tests were performed overall with this new approach. These represent 6.9% of the total number of assays performed per 100 episodes with our previous pre-emptive strategy (n = 1134; P o 0.001). Even limiting the analysis to these 39 episodes in which sGM tests were performed, the new approach significantly reduced the number of tests performed from a median of 11 (range 3-30) to 2 (range 1-5) per high-risk episode (P o 0.001). A large majority of 85.9% assays (67/78) in 84.6% of diagnostic-driven episodes (33/39) were all negative. Only 11 sGM tests (14.1%) were positive in 6 episodes (15.4%).
In the 61 episodes where sGM tests were not performed, the vast majority of patients (55, 90%) remained on posaconazole prophylaxis as planned, survived the episodes and did not develop any other features of IFD. Six other episodes without sGM tests for lack of a clinical suspicion of IFD (10%) discontinued prophylaxis and received intravenous antifungals for a variety of reasons (1 drug interaction, 2 gastrointestinal intolerance and diarrhea and 3 liver dysfunction tests). Only one patient in this group required a chest CT scan, with findings compatible with viral infection. They all survived the risk episodes, discontinued intravenous antifungals and did not develop any other features of IFD (Table 2) .
Among 39 episodes with diagnostic-driven sGM tests, 30 (77%) remained on posaconazole prophylaxis during the whole risk period and did not develop any other features of IFD. Six of these 30 episodes had false positive sGM test results, with normal CT scans (5) and unspecific radiological findings (1). Eleven out of 18 sGM tests performed in these 6 episodes were false positive (median 2, range 1-3 per episode; optical indexes 0.59 to 2.25), and the other 7 tests all negative. In addition, the remaining 24 episodes with diagnostic-driven sGM had all their tests negative (n = 41), 9 with normal CT scans, 5 with unspecific radiological findings, and one each with pleural effusion, bilateral pneumonia and bilateral micro-nodules. Twenty-three survived the episode, and one patient died from hepatic encephalopathy 22 days after a single negative sGM test performed in the setting of initial persistent fever that resolved, remained on posaconazole and had no further fever or any other features of IFD at the time of death (Table 2) .
Finally, nine episodes with diagnostic-driven sGM assays (n = 19; test results all negative) received IV antifungal therapy for the following reasons: five cases had already discontinued posaconazole prophylaxis (one drug interaction, two gastrointestinal intolerance and diarrhea and two liver dysfunction tests) prior to developing a persistent fever that triggered diagnostic-driven sGM testing. Two of them died, one from lymphoma progression and the other one from severe gastrointestinal toxicity and bacterial sepsis. Two episodes received antifungal treatment based on a clinical decision for persistent fever despite empirical antibiotic therapy and no microbiological confirmation otherwise, and both had repeatedly negative sGM test results. One of them died from steroid-refractory acute GvHD, with unspecific changes in the CT scan and no features of IFD. Two final patients developed proven non-Aspergillus breakthrough IFD (2%), namely one Fusarium solani infection and one Candida glabrata infection, both confirmed in blood cultures and both causing IFD-related death 12 and 13 days after diagnosis, respectively, for a low fungalrelated death of 2%, and all-cause mortality rates of 6% in this series. Despite the discontinuation of sGM surveillance in asymptomatic patients, there were no statistical differences in the low incidence of IFD, fungal-related death and all-cause mortality rates between the diagnostic-driven and the previous pre-emptive surveillance strategy of GM use (Table 1C ). In addition, only 15% of the episodes required posaconazole withdrawal and replacement with IV antifungal treatment, 2% for treatment of breakthrough IFD, and 13% for a mix of clinical decisions in the context of persistent fever despite antibiotic therapy, drug toxicity or intolerance. Likewise, the percentage of episodes requiring IV antifungals remained virtually identical between both strategies of GM use (Table 1C) . The discontinuation of twice weekly sGM tests in asymptomatic patients led to a very significant economic impact. The cost of a single sGM assay in our institution is 40.35 €. With our previous pre-emptive strategy, the direct sGM assay total costs performed per 100 high-risk episodes was 45 756.9 € (40.35 € per test × 1 134 sGM assays) compared with only 3 147.3 € after the implementation of the new diagnostic-driven strategy (40.35 € × 78 sGM tests; P o0.001).
Our study provides data to support the proposal that sGM surveillance can be safely withdrawn from the management of high-risk hematology patients on EAMP. We observed no changes compared with our previous pre-emptive surveillance strategy in the low incidence of IFD (2%) or fungal-related and all-cause mortality rates (2 and 6%, respectively). In particular, all 61 cases in which no sGM assays were performed as a result of the change to a diagnostic strategy survived their risk episodes, and 90% of them completed antifungal prophylaxis as planned. In addition, the use of sGM as part of our diagnostic-driven protocol preserved the beneficial impact of the test to rationalize antifungal therapy, [12] [13] [14] which was required in only 15% of the episodes. Beyond the description of feasibility, we recognize that retrospective comparisons with a previous historical series have limitations and may lack power to identify potential differences between strategies in the various endpoints discussed above. Letter to the Editor Nevertheless, our data clearly show improved efficiency in the use of resources, including a marked 93% statistically significant reduction in the total number of sGM assays performed, accounting for over 42 000 € saved in direct sGM costs in this series, as well as preventing asymptomatic patients from unnecessary CT scans and other diagnostic tests triggered by false positive surveillance sGM test results that may mislead clinical decisions. 9 Future antifungal management algorithms in patients on EAMP will need more advanced in vitro diagnostic assays.
10,15 Although we may have to wait for those assays to arrive, we now have preliminary evidence to reconcile a more efficient co-positioning of EAMP to reduce the incidence of IFD and improve patient outcome, and the sGM assay as part of a diagnostic-driven strategy to rationalize antifungal treatment, with an overall goal to improve the efficiency of antifungal management of high-risk hematology patients in real-life clinical practice.
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